Aortoseal (surgical stapler for aortic aneurysm)

2024: Market Entry

In mid-July 2024, a surgical stapler for the treatment aneurysms of abdominal aortas production by the Tel Aviv company entered the market. Endoron Medical

Endoron is developing technologies for endovascular treatment of abdominal aortic aneurysms. The new Aortoseal stapler addresses the critical sealing and fixation problems of endografts used in minimally invasive repair of abdominal aortic aneurysms, especially in complex surgical procedures. The company says its innovative stitching mechanism ensures endografts are fully sealed and securely fixed. This prevents transplants from moving and leaking in the long term and therefore reduces the need for highly invasive open surgery with high mortality.

Medtech Insight - Citeline

Endoron Medical announced the closure of a Series A funding round worth 10 million dollars for the release of a new surgical stapler. Sofinnova Partners led the round by providing relevant contributions from the European Innovation Council Fund (EIC Fund). Endoron said the funding will enable it to benefit from "the opportunity to implement innovative solutions in the endovascular care market."

Sofinnova Partners are popular investors in medical technology. They have a wealth of experience with fast-growing companies like ours, "said Ronit Harpas, co-founder and CEO of Endoron. - I am confident that thanks to their continued support, we will achieve key clinical and regulatory indicators and will be able to implement the use of our EndoStapling technology in clinics. The participation of the EIC further confirms that we must bring this innovative tool to the European medical market.[1]

Notes